Asceneuron

Active#21 in Switzerland

Estimated valuation · Neurodegeneration · Switzerland

Develops small-molecule drugs that target tau and alpha-synuclein pathology, aiming at neurodegenerative diseases such as Alzheimer's and Parkinson's.

Biotech›neurodegeneration asceneuron.com

HQLausanne

Last roundSeries C · Jul 2024

Country of originSwitzerlandListed in the Switzerland ranking

Where would you invest?SwitzerlandJurisdiction as cited by the ranking

Estimated valuation

AI · Switzerland ranking

≈ USD 520MUSD 340–770M · Hundreds of M$

Hundreds of k$

Millions $

Tens of M$

Hundreds of M$

Unicorn

Decacorn

Hectocorn

Anchor: Last known equity round: Series C · USD 100M · Jul 2024
AI adjustment: None

An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method

Uback rankings

How the AI ranks →

Ranking	Tier	Rank	Edition	Next update
Switzerland · all sectors	Top 50	#21	Edition 0 · October 2026	11 Nov 2026

Rank historyOct 2026 · #21First edition: no movements yet.

Funding history

Date	Round	Amount	Type	Investors
Jul 2024	Series C	USD 100M	Equity	—

Rounds as cited by Uback’s rankings. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of Asceneuron as a PDF. It must answer at least one of these four questions, and stick to them:

AI valuation: $520MUndervalued or overvalued?

Versus competitorsHow does it compare?

Who should acquire itStrategic buyers, and why

Who should it acquireAcquisition targets, and why

Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication.

Invest

Back Asceneuron whether or not it has agreed: your intention joins the pool on Asceneuron, passed to the Fundraising Desk of its country once it reaches critical mass. Backing on Uback (pronounced “you back”) means declaring an Interest (free) or an Intention (coming soon). Backing does not mean that this company is raising funds or that a shareholder is selling shares, and it is not a commitment to invest. Any deal, through a funding round or a sale by an existing shareholder, is handled by a partner desk: the Fundraising Desk of the country for a round, the Secondary Sales Desk assigned to the company for a sale.

Back Asceneuron Or back biotech in Switzerland

Pool on AsceneuronBelow threshold

BackersBelow threshold

Paid intention · valid for life · movable until you sign with a partner desk. If the company does not follow up, Uback invites its Backers to move their intentions to a competitor or a similar company. Investing in non-listed companies carries a risk of losing all the capital invested.

Do you run Asceneuron?

Claim this profile to correct data, add your logo and description, or tell Uback about an upcoming round.

Claim this profile Report an upcoming round → Report an error →

Are you a shareholder?

Considering selling some of your shares? Tell Uback privately. Nothing is published without your consent, and never a price or a volume.

Tell Uback privately

What the AI reads

Read by the AI at the next edition.

Comparable companies in Switzerland

Full Switzerland ranking →

Numab Therapeutics#6Biotech › multispecific antibodiesUnicorn Alentis Therapeutics#8Biotech › oncology ADCsHundreds of M$Windward Bio#9Biotech › respiratory antibodiesHundreds of M$Vaderis Therapeutics#10Biotech › rare vascular diseaseHundreds of M$

Last updated: Oct 2026Report an error

Uback is a content publisher and an aggregator of non-binding expressions of interest. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.